CBIS - Cannabis Science, Inc (OTCBB Stock)

[paperchase]

Cannabis Science Enters into Investor Relations Agreement
12:44p ET July 2, 2009 (Business Wire)
Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging cannabis pharmaceutical company, is pleased to announce that the company has retained Catalyst Xchange Corp. (CXC), located in London, Ontario, to provide it with investor relations services under an agreement dated June 30, 2009. Represented by its principals, Don Shaxon and Jason Springett, CXC will provide a variety of promotional and investor relations services to CSI, including assisting with the dissemination of news and information to the public, and, initiating and maintaining contact with investors. As part of its services CXC uses social networking and Internet-based marketing sites.

"We are very pleased to be on board with Cannabis Science for the long run," Don Shaxon from Catalyst Xchange Corp. indicated. "We thoroughly understand the multi-billion dollar pharmaceutical market that the company seeks to enter. Fortunately, Cannabis Science understands it as well and is positioning itself with cannabis-based products, which some hail as the next class of pharmaceutical blockbusters. Cannabis Science has hired the right people, Ray Carr, R.Ph., and Mary Ruwart, Ph.D., to head up the efforts to get the company's unique cannabis-based pharmaceuticals through the FDA approval process. We are focused on immediately assisting this effort by raising share value and investment capital for the company."

Company Website: http://www.cannabisscience.com/

http://www.google.com/finance?q=OTC:CBIS

[paperchase]

CSI Appoints Dr. Robert Melamede, Ph.D., Former Chairman of the Biology Department at University of Colorado, Colorado Springs, As President & CEO
9:12a ET July 9, 2009 (Business Wire)
Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased to announce the appointment of Dr. Robert J. Melamede, Ph.D., as President & CEO, replacing Steven W. Kubby in that position. Mr. Kubby will remain as a Director and the company is in discussions with him about his future role.

Dr. Melamede has previously served as the Chief Science Officer of Cannabis Science Inc, and will continue in that capacity as well. Dr. Melamede retired as Chairman of the Biology Department at University of Colorado, Colorado Springs in 2005, where he continues to teach.

Dr. Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. He Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabis, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. Dr. Melamede also serves on the Advisory Board of The Journal of the International Association for Cannabis as Medicine, and the Scientific Advisory Board Medical of the Marijuana Policy Advocacy Project, as well as the Scientific Advisory Board of Americans for Safe Access. He also served as a director of Newellink Inc, a Colorado-based company specializing in cancer research.

The global market for oral cannabis medications has been recently estimated at almost $6 billion annually. Cannabis Science proprietary delivery systems, which insure rapid absorption with prolonged blood levels of active drug, are expected to give the company's products a competitive edge worldwide

[paperchase]

The New Cannabis Science President & CEO Dr. Melamede Reports FDA Progress Plans And New Management Team Objectives for its Cannabis Formulations
9:36a ET July 17, 2009 (Business Wire)
Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased to announce that the Company is moving forward confidently under the guidance of its new President & CEO, Dr. Robert Melamede Ph.D. The planning for the company's product line up remains the same, including its FDA fast track initiatives. In the light of recent corporate management changes, Dr. Melamede has begun negotiating with high level industry executives to build a new team with both FDA protocol and research experience to work on Cannabis Science's extensive product line up and rapid market entry initiatives. The former CEO, Steven W. Kubby, has now resigned from the Board of Directors, and his team members Dr. Mary Ruwart, and Mr. Ray Carr have resigned from their positions with Cannabis Science. The Company wishes them the best in their future endeavors.

Dr. Melamede, states, "I wholeheartedly welcome the opportunity to assemble my own management team to progress the outstanding formulations we have to immediately target and immobilize critical illnesses worldwide through the FDA and other government regulated distribution channels."

Richard Cowan, Cannabis Science CFO, who also remains on the Board with Dr. Melamede, added, "I think that Dr. Melamede's extensive contacts in the scientific community, where he is greatly respected, and his collaborative management style will make it much easier for the company to recruit the talent that is needed to accomplish our goals while progressing our substantial list of formulas including pioneering methods for developing, producing and commercializing a variety of effective whole plant cannabinoid based pharmaceutical products using certified organic production methods to ultimately produce certified organic products."

In keeping with both the historic medical uses of cannabis and the new scientific understanding of how cannabinoids work, there are numerous multi-billion dollar markets globally that will be addressed with Cannabis Science formulations. The Cannabis Science cannabinoid formulations can target a wide-variety of serious needs such as:

1. Chronic pain, to reduce or eliminate patients' dependence on opiates.

2. Neuropathic pain, related to spinal cord injuries, as well as conditions such as AIDS/HIV and the side-effects of its medications, etc. for which opiates are not very effective.

3. Neuro-muscular disorders, such as MS.

4. Respiratory inflammation, related to both infections such as avian flu and to immune imbalance such as asthma.

5. The control of numerous cancers and their metastasis.

6. Cancer, including pain management, control of nausea resulting from chemotherapy as well as loss of appetite related to the disease itself

7. Digestive illnesses, such as gastroesophageal reflux disease (GERDS), Crohn's Disease and irritable bowel syndrome.

8. Dermatological irritations and infections such as MRSA (flesh eating disease).

9. Sleep disorders.

In each of these areas, cannabis has been proven to work, so we will have targeted formulations, which the Company plans to release via one or more of the four types of pharmaceutical product categories targeted:

1. Possible over-the-counter Pharmaceutical Products:

a) Non-Prescription Drugs (With disease specific claims)

b) Nutraceuticals (No disease specific claims)

2. Possible Prescription Pharmaceutical Medications:

a) Psychoactive Medications

b) Non-Psychoactive Medications

Dr. Melamede has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York. Dr. Melamede is recognized as a leading authority on the therapeutic uses of cannabis, and has authored or co-authored dozens of papers on a wide variety of scientific subjects. Dr. Melamede also serves on the Advisory Board of The Journal of the International Association for Cannabis as Medicine, and the Scientific Advisory Board Medical of the Marijuana Policy Advocacy Project, as well as the Scientific Advisory Board of Americans for Safe Access.

[paperchase]

Dr. Melamede Confirms Pre-IND Procedures Are in Motion for Pre-IND Meeting With the FDA and Plans Corporate Headquarters Move to Colorado Springs, Colorado
5:57a ET July 20, 2009 (Market Wire)
Cannabis Science Inc. (OTCBB: CBIS), an emerging cannabis pharmaceutical company, is pleased to announce that the Company is moving forward with its preparations for a pre-IND meeting with the FDA, which will provide guidance on the manufacturing, non-clinical, and clinical development program for Cannabis Science Drugs. As well the Company reports intentions to move corporate headquarters to Colorado Springs, Colorado. Dr. Melamede is currently in discussion with facilities in the Colorado Springs area.

"It is very important to understand that our initial drug formulation is ready now, which often costs major pharmaceutical companies millions of dollars to reach this stage. Our initial pre-IND work will establish non-clinical product safety (safety pharmacology, pharmacokinetics, and toxicology) under FDA guidelines. We are also identifying and establishing appropriate GMP compliant testing and manufacturing facilities. If the assumptions we make about pre-existing information are accurate, our costs in time and money to get to the pre-IND meeting with the FDA will be much less because our initial drug formulation is ready now. We look forward to working with the FDA and to following their recommendations with the steps that are required to ultimately produce our first FDA approved pharmaceutical product," stated, Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. It is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

[paperchase]

CSI President Dr. Robert Melamede Testified Yesterday at Denver Hearing Which Stopped Attempt to Restrict Patients' Access to Medical Marijuana; Cannabis Science Plans for End of Marijuana Prohibition
12:12p ET July 21, 2009 (Market Wire)
Cannabis Science Inc. (OTCBB: CBIS), an emerging cannabis pharmaceutical company, is proud to report that its CEO, Dr. Robert Melamede, Ph.D., spoke yesterday at a Denver hearing in opposition to an attempt to undermine a voter-approved constitutional amendment allowing the use of marijuana for medical purposes.

Colorado's state health board voted 6-3 Monday night to reject a move to limit suppliers of medical marijuana to helping only five patients at a time. Dr. Melamede pointed out that such restrictions would make it much more difficult for patients to get affordable medical marijuana.

Dr. Melamede explained, "Although Cannabis Science is committed to developing cannabis-based pharmaceuticals for FDA approval, the company's business strategy is based on the assumption that marijuana prohibition will end, and its products will have to compete with 'over-the-counter' products of the sort already available in medical marijuana dispensaries."

According to the Associated Press, there are 9,112 people registered to use medical marijuana in Colorado, up 2,000 just in the last month. Ron Hyman, the state health department registrar who oversees the medical marijuana registry, predicted that 15,000 people will be signed up by the end of the year. This rapid growth demonstrates the huge need for cannabis-based medicines.

Cannabis Science Inc. is at the forefront of medical marijuana research and development. The company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. It is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

[paperchase]

Today's Wall Street Journal Reports on Cannabis Science Inc. in Article on Booming Medical Cannabis Industry; Indicates Great Demand for Products From a Patient Oriented Company
9:55a ET July 23, 2009 (Market Wire)
Cannabis Science Inc. (OTCBB: CBIS), an emerging pharmaceutical cannabis company, is pleased that today's Wall Street Journal article on the booming medical cannabis industry in California notes the role of Cannabis Science Inc.

Commenting on why Cannabis Science was mentioned in the article, Richard Cowan, chief financial officer of Cannabis Science Inc., said, "Although the company is beginning the FDA approval process for its products, we believe that the inclusion of Cannabis Science Inc. in an article about the struggle to get medical cannabis to patients is further evidence that we are a patient oriented company, whose business strategy does not depend on a continuation of marijuana prohibition."

Although the company is not involved in the state's gray market, the article notes, "A pot activist named Richard Cowan has opened what he envisions as an investment bank for pot-related businesses, called General Marijuana (General Marijuana.com). Mr. Cowan is also chief financial officer of Cannabis Science Inc., which is trying to market a pot lozenge for nonsmokers." Please click Medical Marijuana in California Aspires to Go Commercial - WSJ.com to read the article in full.

Cannabis Science CEO, Dr. Robert J. Melamede, observed, "This article is further demonstration of the huge need for FDA approved medical cannabis products."

Earlier this week, Cannabis Science reported that Dr. Melamede had spoken at a hearing in Denver in opposition to an attempt to undermine a voter-approved constitutional amendment that would have made it much more difficult for patients to get affordable medical marijuana.

Cannabis Science Inc. is at the forefront of medical marijuana research and development. The company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. It is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

[paperchase]

Today's CNN Pandemic Report on H1N1 Pushes Cannabis Science to Move Faster to Release Its Anti-Inflammatory Cannabis Drug as Similarities Between 2009 and Deadly 1918 Influenza Pandemic Cause Concern; FDA Approved Drugs Needed Now to Meet This Urgent Situation
11:19a ET July 24, 2009 (Market Wire)
Cannabis Science Inc. (OTCBB: CBIS), an emerging pharmaceutical cannabis company, is making its anti-inflammatory formulation that targets influenza symptoms one of its top priority drugs to release, as the latest Swine flu numbers are rapidly increasing and have become quite alarming. Research indicates that the current H1N1 influenza virus has disturbing similarities to the 1918 pandemic, which killed tens of millions after World War I. Moreover, the young and otherwise healthy population that has been most susceptible to the H1N1 virus is a similar demographic to those most affected in the 1918 outbreak.

Swine flu, Bird Flu and all influenza strains that elicit excessive inflammatory immune response are targeted with Cannabis Science formulations. The company is developing its strategy for studying the effects of its cannabis lozenge on influenza deaths that are associated with an excessive inflammatory response. A hyper-inflammatory response appears to be the cause of the high mortality (63%) associated with the Avian flu (H5N1), and recent studies indicate a similar risk with the Swine flu (H1N1) as well. The World Health Organization (WHO) released the latest figures and said the virus was "unstoppable" and had become widespread enough to raise the global Swine flu alert to its highest level.

Dr. Robert Melamede, Ph.D., Cannabis Science Inc. President & CEO, observed, "Contemporary anti-viral medical technology is currently inadequate to meet the World's immediate challenges in dealing with the rapid mutations and infectivity of the numerous influenza viruses. We believe that cannabis extract-based medicines can reduce influenza deaths, and allow infected individuals to develop a strong natural immunity upon recovery."

Specifically, Cannabis Science Inc. believes that its whole-cannabis extract lozenge will inhibit the development of ARDS (Adult Respiratory Distress Syndrome) associated with deaths from both the Avian and Swine influenza infections. Dr. Melamede believes there is enormous potential value for cannabinoids that naturally prevent excessive inflammatory immune responses. He stated, "Based upon recent discoveries regarding the role that endocannabinoid system plays in maintaining human health, we may have a unique solution to the looming threat posed by deadly influenza strains, which we believe, if implemented, could save millions of lives."

Previously, Dr. Melamede urged all cannabis consumers, "If you come down with the flu, cease smoking and switch to edibles. We believe that smoking marijuana when a person has influenza will lead to some unnecessary deaths, whereas eating it can prevent unnecessary deaths."

[BadThad]

CBIS? HAHAHAHAHA, how cool of a company is that!

[CatFish]

well i took the proceeds from some of my shares of the stock that must not be named and bought some cbis at .80. i figure i must have been high to buy the stock that must not be named so why not get some of cbis Cannabis Science, Inc

[CatFish]

Cannabis Science to Apply to the FDA to Utilize Their Fast Track Procedures to Help Speed the Approval of Its Cannabinoid Medicines in Treatment of H1N1 Swine Flu as AP Report Predicts Swine Flu Could Hit up to 40 Percent in the USA
Press Release
Source: Cannabis Science, Inc.
On Monday July 27, 2009, 1:23 pm EDT
Cannabis science, inc.
SAN FRANCISCO, CA--(Marketwire - 07/27/09) - Cannabis Science, Inc. (OTC.BB:CBIS - News), an emerging pharmaceutical cannabis company, is pleased to report that it is moving as fast as possible to assist in the fight against the threat of a deadly influenza pandemic. In conjunction with its recent re-organization, the Company has begun discussions with the FDA as its program moves forward to provide FDA approved solutions for several critical illnesses.


According to the CDC (CDC - Influenza (Flu) |Avian Flu) the Avian flu (H5N1) has a 63% mortality rate. Unfortunately, the Swine flu, while causing death at a much lower rate than the Avian flu, appears to also result in death via a similar mechanism. The common cause of death with these strains is organ failure, especially as seen in the lungs with the development of Adult Respiratory Distress Syndrome (ARDS). ARDS is caused by an excess immune-generated inflammatory response that leads to apoptosis (cell death) and subsequently to organ failure. The Company's approach will mimic how the human body uses endocannabinoids (cannabinoids that occur naturally in the body) to regulate immune activity and cell survival, by regulating inflammatory biochemistry. Excessive inflammatory responses are associated with numerous disease states including autoimmune diseases, neurological imbalances, and cardiovascular disease. Phytocannabinoids provide a natural means to supplement illness-specific endocannabinoid deficiencies.

Cannabis Science H1N1 Swine Flu Formulation:

We now know that the endocannabinoid system plays a critical role in maintaining human health. The human body produces Endocannabinoids on demand when they are needed. They help restore homeostasis (biochemical balance). The Cannabis plant produces Phytocannabinoids. When the human body has endocannabinoid deficiencies, it cannot effectively restore the healthy biochemical state needed to counter a particular illness. Phytocannabinoids from the Cannabis plant can replace the deficient endocannabinoid activity in the human body to restore a health-promoting level of cannabinoid activity. Cannabis Science will test its cannabis extract lozenge with FDA guidance and oversight to determine if it will reduce ARDS-associated deaths from both the Avian and Swine influenza infections.

Dr. Robert Melamede, Ph.D., Cannabis Science, Inc., President and CEO, believes there is enormous potential value for cannabinoids to naturally reduce excessive inflammatory immune responses, and the Cannabis Science lozenge formulation could reduce the mortality rate and allow infected individuals to develop a strong natural immunity upon recovery. Dr. Melamede is the former Chairman (ret) of the Biology Department at the University of Colorado (Colorado Springs.)

Dr. Melamede added, "Again, we recommend, based on sound scientific principles, that medical marijuana users should switch to edibles if they come down with an influenza infection. We believe that the irritation associated with the pulmonary route, when a person has an influenza infection, may lead to unnecessary deaths. In contrast, oral administration may prevent many deaths. We hope that due to the magnitude of this pandemic threat, that the FDA will fast track our proposal."

FDA's three rapid special drug release programs:

Fast Track, Accelerated Approval and Priority Review are approaches that are intended to make therapeutically important drugs available at an earlier time. They do not compromise the standards for the safety and effectiveness of the drugs that become available through this process. These revitalized FDA drug review approaches have yielded tangible results in bringing safe and effective drugs to patients with serious diseases more quickly. For example, since 1996, 68 drugs for cancer therapies have received priority review and approval. The FDA reviewed Gleevec, a treatment for chronic myeloid leukemia, in four months. Shortened review times have also brought promising treatments to patients with HIV/AIDS more quickly. Kaletra for the treatment of HIV/AIDS was reviewed and approved in 3.5 months. Pegasys, a combination product for the treatment of Hepatitis C, was approved for marketing in 4 months.

Fast Track, Accelerated Approval, and Priority Review have evolved over time. The FDA has been vigilant in assuring that reducing the time necessary for drug development has not compromised the safety and effectiveness of drugs for patients with serious diseases. The median time required to review a priority review drug was reduced from 13.9 months to 6.7 months.